← Back to news
ResearchRSSFriday, May 15, 2026 · May 15, 2026

Protein changes may help explain Spinraza response in SMA

WHY IT MATTERS

Understanding which protein changes in cerebrospinal fluid predict Spinraza response could help doctors identify which SMA patients are most likely to benefit from treatment and potentially guide future treatment decisions.

Researchers studied how Spinraza, a medicine for spinal muscular atrophy (SMA), changes certain proteins in the fluid around the brain and spinal cord. They found that these protein changes happen when the medicine works, and some of these changes match up with patients getting stronger and moving better. This helps doctors understand why the medicine helps some patients.

Treatment with Spinraza (nusinersen) was linked to measurable changes in a range of cerebrospinal fluid (CSF) biomarkers in people with spinal muscular atrophy (SMA), some of which were associated with improvements in motor function, according to a review of published studies. Among the protein changes seen in CSF, the liquid that surrounds the brain and […] The post Protein changes may help explain Spinraza response in SMA appeared first on SMA News Today .

ASK YOUR DOCTOR

If you or your child is currently on Spinraza or considering it, ask your neurologist whether CSF biomarker testing might be available to help monitor treatment response.

Find a specialist →Learn more ↗
biomarkerscerebrospinal fluidtreatment responsemotor functionprotein changes

Related conditions

Spinal muscular atrophy associated with central nervous system anomalySpinal muscular atrophy with respiratory distress type 2Spinal muscular atrophy with respiratory distress type 1

Related news

Researchbiorxiv · May 13, 2026
Preprint: GPNMB and glycosphingolipid measurements in cerebrospinal fluid and plasma from Parkinson's disease patients in the BioFind cohort
Researchers studied two proteins called GPNMB and glycosphingolipids in blood and spinal fluid samples from Parkinson's